Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Crosby

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2016
An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton PlanningSamantha Warren, Mike Partridge, Alessandra Bolsi, et al.
Radiation Oncology (London, England)|November 21, 2015
The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigationRhys Carrington, John Staffurth, Samantha Warren, et al.
Clinical Genitourinary Cancer|March 27, 2026
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective StudyBenjamin Thomas Crosby, Steffanie Winsor, Alice Spurr, et al.
BMJ Open Quality|January 30, 2025
Impact of introducing transnasal endoscopy on expanding diagnostic endoscopy servicesBen Thomas Crosby, Laura Munglani, Karen Wright, et al.
The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.
The Lancet. Oncology|February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trialDavid Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axisBruno Beernaert, Rose L Jady-Clark, Parin Shah, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
International Journal of Radiation Oncology, Biology, Physics|April 17, 2016
An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton PlanningSamantha Warren, Mike Partridge, Alessandra Bolsi, et al.
Radiation Oncology (London, England)|November 21, 2015
The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigationRhys Carrington, John Staffurth, Samantha Warren, et al.
Clinical Genitourinary Cancer|March 27, 2026
Real-World Outcomes of First-Line Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma: A UK Multi-Centre Retrospective StudyBenjamin Thomas Crosby, Steffanie Winsor, Alice Spurr, et al.
BMJ Open Quality|January 30, 2025
Impact of introducing transnasal endoscopy on expanding diagnostic endoscopy servicesBen Thomas Crosby, Laura Munglani, Karen Wright, et al.
The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.
The Lancet. Oncology|February 7, 2017
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trialDavid Cunningham, Sally P Stenning, Elizabeth C Smyth, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axisBruno Beernaert, Rose L Jady-Clark, Parin Shah, et al.
Pageof 2